These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7911308)

  • 41. Effect of age on the pharmacokinetics of orally and intravenously administered terazosin.
    Sennello LT; Sonders RC; Glassman HN; Jordan DC; Luther RR; Tolman KG
    Clin Ther; 1988; 10(5):600-7. PubMed ID: 2908805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intraoperative floppy iris syndrome associated with alpha1-adrenergic receptor antagonists.
    Cantrell MA; Bream-Rouwenhorst HR; Steffensmeier A; Hemerson P; Rogers M; Stamper B
    Ann Pharmacother; 2008 Apr; 42(4):558-63. PubMed ID: 18364408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of alpha-1 adrenergic receptor antagonist, terazosin, on cardiovascular functions in anaesthetised dogs.
    Sharma R; Ahuja VM; Fahim M
    Indian J Exp Biol; 2004 Dec; 42(12):1195-9. PubMed ID: 15623230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Terazosin in the treatment of benign prostatic hypertrophy].
    Andres M; De Cobelli O; Carmignani L; Musci R; Kocjancic E; Panizzutti M; Rocco F
    Arch Ital Urol Androl; 1995 Feb; 67(1):37-9. PubMed ID: 7538386
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension.
    Deger G
    Am J Med; 1986 May; 80(5B):62-7. PubMed ID: 2872809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Djavan B; Marberger M
    Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New-onset priapism associated with ingestion of terazosin in an otherwise healthy man.
    Sadeghi-Nejad H; Jackson I
    J Sex Med; 2007 Nov; 4(6):1766-8. PubMed ID: 17451488
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Therapy of benign prostatic hyperplasia: terazosin or finasteride?].
    Trinkler FB
    Praxis (Bern 1994); 1997 Aug; 86(34):1305-6. PubMed ID: 9381019
    [No Abstract]   [Full Text] [Related]  

  • 49. [Quantitative analyses of human prostatic alpha-adrenoceptors and effects of terazosin on the alpha-adrenoceptor activity].
    Morita T
    J Smooth Muscle Res; 1991 Jun; 27(3):149-54. PubMed ID: 1726720
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertension.
    Luther RR; Glassman HN; Estep CB; Schmitz PJ; Horton JK; Jordan DC
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):237S-240S. PubMed ID: 2901267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of the pharmacokinetic-pharmacodynamic interaction between terazosin and finasteride.
    Samara EE; Hosmane B; Locke C; Eason C; Cavanaugh J; Granneman GR
    J Clin Pharmacol; 1996 Dec; 36(12):1169-78. PubMed ID: 9013375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.
    Vincent J; Dachman W; Blaschke TF; Hoffman BB
    J Clin Invest; 1992 Nov; 90(5):1763-8. PubMed ID: 1358918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Β-Adrenergic agonist administration is not associated with secondary carcinoid crisis in patients with carcinoid tumor.
    Limbach KE; Condron ME; Bingham AE; Pommier SJ; Pommier RF
    Am J Surg; 2019 May; 217(5):932-936. PubMed ID: 30635207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experience with terazosin administered in combination with other antihypertensive agents.
    Chrysant SG
    Am J Med; 1986 May; 80(5B):55-61. PubMed ID: 2872808
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative trials of terazosin with other antihypertensive agents.
    Ruoff G
    Am J Med; 1986 May; 80(5B):42-8. PubMed ID: 2872806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.
    Lepor H; Meretyk S; Knapp-Maloney G
    J Urol; 1992 Jun; 147(6):1554-7. PubMed ID: 1375659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Noninvasive continuous detection of arterial hypotension during induction of anaesthesia using a photoplethysmographic signal: proof of concept.
    Coutrot M; Joachim J; Dépret F; Millasseau S; Nougué H; Matéo J; Mebazaa A; Gayat E; Vallée F
    Br J Anaesth; 2019 May; 122(5):605-612. PubMed ID: 30916032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors.
    Harada K; Ohmori M; Kitoh Y; Sugimoto K; Fujimura A
    Jpn J Pharmacol; 1999 Jul; 80(3):209-15. PubMed ID: 10461765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of withdrawal of terazosin therapy in patients with hypertension.
    Ruoff G
    Am J Med; 1986 May; 80(5B):35-41. PubMed ID: 2872805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group.
    Lepor H
    Urology; 1995 Mar; 45(3):406-13. PubMed ID: 7533452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.